07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

3PO: Phase I started

Advanced Cancer Therapeutics began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV PFK-158, with a starting dose of 24 mg/m 2, in up to 48 patients with advanced solid tumors, including melanoma and...
08:00 , Dec 15, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Leukemia c-Myc (MYC) In vitro studies suggest genomic c-Myc quadruplex DNA could be used to treat leukemia. In human leukemic cell lines, an oligonucleotide encoding...
07:00 , Jul 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Infectious disease Macrophage migration inhibitory factor (MIF) Studies in mice suggest inhibiting MIF could help treat arthritis associated with the Ross River virus (RRV)....
07:00 , May 19, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Sepsis Macrophage migration inhibitory factor (MIF) In vitro, mouse and patient studies suggest inhibiting MIF with the thyroid hormone thyroxine...
07:00 , May 19, 2011 |  BC Innovations  |  Targets & Mechanisms

Thyroxine: MIFfed about sepsis

A U.S. research team has shown that d-thyroxine, an old hyperlipidemia drug from Abbott Laboratories ,...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Financial News

Advanced Cancer Therapeutics completes venture financing

Advanced Cancer Therapeutics LLC , Louisville, Ky.   Business: Cancer   Date completed: 7/1/10   Type: Venture financing   Raised: $10 million   Investors: Individual investors; and other investors  ...
00:51 , Jul 2, 2010 |  BC Extra  |  Financial News

Advanced Cancer Therapeutics raises $10 million

Advanced Cancer Therapeutics LLC (Louisville, Ky.) raised $10 million in seed financing from undisclosed high net-worth individuals and institutions in Kentucky. The company has three lead programs to treat cancer: small molecule inhibitors for 6-phosphofructo-2-kinase...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Clinical News

Advanced Cancer Therapeutics preclinical data

Researchers at the University of Louisville published in Oncogene that selective inhibition of choline kinase (CHK) expression simultaneously attenuated two cellular signaling pathways required for cancer cell growth and survival - the mitogen activated protein...
07:00 , Jun 8, 2009 |  BC Week In Review  |  Company News

Advanced Cancer Therapeutics, University of Louisville deal

Advanced Cancer received exclusive, worldwide rights from the university's James Graham Brown Cancer Center to develop and commercialize CK37 . The small molecule inhibitor of choline kinase (CHK) is in preclinical testing for cancer. The...
07:00 , Aug 25, 2008 |  BC Week In Review  |  Company News

Advanced Cancer Therapeutics management update

Advanced Cancer Therapeutics LLC , Louisville, Ky.   Business: Cancer   Hired: Gilles Tapolsky as CSO, formerly VP of product development at Tapestry Pharmaceuticals Inc.  ...